Publications scientifiques

2614 PUBLICATIONS

ANNÉE

JOURNAL

PREMIER AUTEUR

TITRE

ANNÉE2022

JOURNALBMC cancer

PREMIER AUTEURBruand M

TITREAcute skin toxicity of conventional fractionated versus hypofractionated radiotherapy in breast cancer patients receiving regional node irradiation: the real-life prospective multicenter HYPOBREAST cohort.

ANNÉE2022

JOURNALFrontiers in oncology

PREMIER AUTEURNeuville C

TITRENivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.

ANNÉE2022

JOURNALFrontiers in oncology

PREMIER AUTEURDardare J

TITREDDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy.

ANNÉE2022

JOURNALFrontiers in oncology

PREMIER AUTEURSpira A

TITREIdentification of as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer.

ANNÉE2022

JOURNALBiochimica et biophysica acta. Molecular basis of disease

PREMIER AUTEURLirussi F

TITREPlasma membrane lipid bilayer is druggable: Selective delivery of gemcitabine-squalene nano-medicine to cancer cells.

ANNÉE2022

JOURNALRadiation oncology (London, England)

PREMIER AUTEURDemogeot N

TITREImpact of fractionated stereotactic radiotherapy on activity of daily living and performance status in progressive/recurrent glioblastoma: a retrospective study.

ANNÉE2022

JOURNALFrontiers in immunology

PREMIER AUTEURBrisebarre A

TITRETranscriptomic FHIT/pHER2 signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer.

ANNÉE2022

JOURNALImmunologic research

PREMIER AUTEURDa Rocha MN

TITRECoated recombinant target protein helps explore IL-1RAP CAR T-cell functionality in vitro.

ANNÉE2022

JOURNALAnticancer research

PREMIER AUTEURBeige A

TITREEfficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.

ANNÉE2022

JOURNALCancer cell international

PREMIER AUTEURDouyère M

TITRENRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells.

Retrouvez aussi

Unités de recherche, établissements

Projets de recherche

Publications scientifiques